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Incidence of Basal Cell Carcinoma Multiplicity and
Detailed Anatomic Distribution: Longitudinal Study
of an Australian Population
Naomi M. Richmond-Sinclair1,2, Nirmala Pandeya1, Robert S. Ware3, Rachel E. Neale1, Gail M. Williams3,
Jolieke C. van der Pols1 and Ade`le C. Green1
A proportion of individuals are affected multiple times by basal cell carcinoma (BCC), but the rate and extent to
which this occurs is unknown. We therefore prospectively estimated BCC incidence in a subtropical Australian
population, focusing on the rate at which persons develop multiple primary BCCs and the precise anatomic
sites of BCC occurrence. Between 1997 and 2006, 663 BCCs were confirmed in 301 of 1,337 participants in the
population-based Nambour Skin Cancer Study. The incidence of persons affected multiple times by primary
BCC was 705 per 100,000 person years compared to an incidence rate of people singly affected of 935 per 100,000
person years. Among the multiply and singly affected alike, site-specific BCC incidence rates were far highest on
facial subsites, followed by upper limbs, trunk, and then lower limbs. We conclude that actual BCC tumor
burden is much greater in the population than is apparent from normal incidence rates. Anatomic distribution
of BCC is consistent with general levels of sun exposure across body sites.
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INTRODUCTION
Basal cell carcinoma (BCC) is the predominant skin cancer in
Caucasian populations (Zedan et al., 2001) and its treatment
imposes a substantial economic burden (Mathers et al., 1999;
Joseph et al., 2001). Because of its high frequency and low
mortality, BCCs are not routinely registered (Green and
MacLennan, 1989) and incidence estimates have largely come
from ad hoc studies. The highest reported incidence rates are in
Australia where 1–2 persons per 100 are affected by BCC
each year (Staples et al., 2006), an order of magnitude higher
than corresponding estimates in Europe and North America
(Bath-Hextall et al., 2007; Karagas et al., 1999).
The incidence of persons affected by BCC is likely to
substantially underestimate the true incidence of this cancer
due to the common occurrence of multiple primary tumors
within individuals synchronously or at different times. In New
Hampshire, USA, multiple BCCs occurred in 16% of affected
patients in a 2-year period (Karagas et al., 1999), whereas in a
tropical Australian community, 26% of BCC patients were
treated for multiple BCCs in a 3-year period (Raasch and
Buettner, 2002), though whether these were diagnosed at the
same or different times was unclear. To date the only detailed
prospective study of BCC tumor incidence involved intensive
skin examination surveys where there was evidence that
more BCCs were being diagnosed due to increased surveil-
lance (Valery et al., 2004). Thus, the extent of the public
health burden of routinely treated, multiple BCCs, remains
unknown.
BCC incidence has a strong inverse relationship with
latitude (Giles et al., 1988); in general, chronically sun-
exposed parts of the body develop a larger proportion of
BCCs than those with less or infrequent exposure (Raasch
et al., 1998). Incidence has rarely been documented
according to detailed anatomic subsites, and never in regard
to multiplicity of BCC tumor occurrence.
Over the past decade we have closely monitored the
occurrence of BCC, including multiple primary BCCs, in a
subtropical Queensland community sample. We report here
the results of this detailed longitudinal assessment of BCC
incidence.
RESULTS
Study population
Of the 1,337 ongoing participants in the Nambour Skin
Cancer Study on 1 January 1997, 1,244 (93%) had complete
follow-up until 31 December 2006, 92 (7%) participants died
during follow-up and one person withdrew from the study. At
baseline in 1997, the mean age of this cohort was 54 years
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and 56% were female (Table 1). Apart from a borderline
difference (P¼ 0.05) with regard to age distribution, the
1,337 participants in the present study were no different from
the 1,621 participants who took part in a preceding skin
cancer prevention trial (Table 1) and were representative of
the original randomly selected Nambour Skin Cancer Study
population (Green et al., 1994). Among the 1,337 partici-
pants, 18% had a known history of BCC before 1997, and of
these, 17% had experienced multiple primary BCCs.
Incidence estimates
During the 10-year period, 663 BCCs were diagnosed within
the cohort: 394 primary tumors in 151 men and 269 tumors
in 150 women (Table 2). The overall age-standardized
incidence rate of BCC was 1,541 people affected per
100,000 person years at risk (pyar, 95% confidence interval
(CI) 1,286–1,829), 1,813 per 100,000 pyar among men and
1,269 per 100,000 pyar among women. Incidence increased
with age and was generally higher in men than women in
each age group.
Single BCC
Of those affected by BCC in the 10-year period, 162 (54%)
persons developed one BCC only. Incidence of persons
affected by a single BCC was 630 per 100,000 pyar in men
under 40 years, rising to 2,614 per 100,000 pyar (95% CI
2,014–3,236) after age 60 years (Table 2). Incidence of
women with only one BCC was very low before age 40 years
(one person affected) but rose thereafter.
Multiple BCCs
Among all those affected by BCC in the 10-year period, 46%
(139 persons) developed multiple BCCs (range 2–28 BCCs).
Of those multiply affected, 56% developed 3 or more, 26% 4
or more, and 17% developed 5 or more BCCs. The median
time between BCCs decreased as a person developed
successively more, but not in a proportionate manner. The
median time between fourth and fifth BCCs (23 months) was
less than half than that between first and second (57 months).
A total of 41 people (29%) were diagnosed with two or more
BCCs on the same date in the 10-year period.
The incidence of people affected by more than one BCC
was 705 per 100,000 pyar (95% CI 539–905), 877 and 533
per 100,000 pyar in men and women, respectively (Table 2).
For both sexes incidence of multiple BCCs increased steadily
with age but was low before age 40 years. More men than
women were affected by multiple BCCs.
Anatomic distribution
Facial sites had by far the highest BCC incidence with peak
rates seen on the nose (around 5.2 per 1,000 pyar), followed
by forehead/temple, then cheek/perioral region, and then ears
(Table 3). However, when unit surface area was accounted
for, rank order noticeably altered. While nose maintained the
highest rates (around 2,100 per 1,000 body units per year),
followed by cheek/perioral region, then eyes, and then
forehead/temple (Table 3). Surface-area-standardized inci-
dence on the limbs was the next highest, then the trunk
whose rate was 1/100th of that on the nose or cheek.
Considering specific subsites, the upper arms and trunk had
similar surface-area-standardized incidence rates. Anatomic
distribution did not vary by sex or by number of BCCs treated
in the 10-year period.
Incidence rates were compared among those assigned to
regular sunscreen use (active intervention) and discretionary
sunscreen use (control arm) during the preceding field trial
and showed no material differences in person- or tumor-
based incidence of BCC.
DISCUSSION
We comprehensively analyzed the incidence rates and sites
of occurrence of BCC in a subtropical Australian community
over a 10-year period, with a focus on people affected by
multiple BCCs. The incidence of people treated for new
primary BCCs was 1.5% in 10 years, confirming the
extraordinarily high incidence of BCC in white populations
residing at low latitudes (Green et al., 1996; Buettner and
Raasch, 1998; Valery et al., 2004) compared to European and
North American populations living in temperate climates
(Karagas et al., 1999; Bath-Hextall et al., 2007).
Table 1. Characteristics of participants of a skin
cancer prevention trial 1992–1996 who were followed
up and not followed up 1997–2006
Original 1992 community-based
trial participants (n=1,621)
Characteristic
Followed up
(n=1,337)
Not followed
up (n=284) P-value
Sex
Female 749 (56%) 162 (57%)
Male 588 (44%) 122 (43%) 0.75
Age at start of Nambour trial in 1992 (years)
20–39 361 (27%) 94 (33%)
40–59 650 (49%) 117 (41%)
60+ 326 (24%) 73 (26%) 0.05
Skin color
Fair 739 (55%) 156 (55%)
Medium 504 (38%) 110(39%)
Olive 93 (7%) 17 (6%) 0.82
Occupational sun exposure
Mainly outdoors 249 (19%) 54 (19%)
Both indoor and outdoor 494 (37%) 107 (38%)
Mainly indoors 593 (44%) 122 (43%) 0.93
Previous basal cell carcinoma (before 1997)
Yes 234 (18%) 38 (13%)
No 1,103 (82%) 246 (87%) 0.09
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Nearly 50% of people routinely treated for BCC developed
multiple primary BCCs during 10 years of observation. This is
broadly consistent with previous observations that 43% of
people affected by BCC developed a subsequent BCC within
4.5 years of active surveillance in the same population
(Pandeya et al., 2005) and those of a meta-analysis of seven
independent studies, which showed the mean 3-year risk of
BCC to be 44% after an initial diagnosis of BCC in North
America (Marcil and Stern, 2000). Our estimate of over 700
persons per 100,000 person years affected by multiple BCCs
is striking and gives some indication why treatment of BCC
consumes a substantial proportion of annual health spending
in Australia (Australian Institute of Health and Welfare
(AIHW), 2005), North America (Chen et al., 2001), and
Europe (Morris et al., 2005).
Our data indicate that the time between subsequent BCCs
decreases with successive BCCs in an individual, which has
implications for the clinical follow-up of BCC patients. Early
detection and treatment of subsequent primary BCCs could
be enhanced by encouraging regular personal skin inspection
and professional skin examinations after an initial BCC
diagnosis (Stern, 1999; Valery et al., 2004).
We calculated the site-specific incidence of BCC standar-
dized for the surface area of anatomic subsites. The
standardization by unit surface area allowed the direct
comparison of BCC tumor burden per unit area of skin taking
into account large differences in surface area among body
sites. We confirmed that the distribution of BCC across
anatomic sites is consistent with level of sun exposure, in
agreement with other studies (Franceschi et al., 1996;
Bastiaens et al., 1998; Buettner and Raasch, 1998), though
the actual site-specific rates per unit surface area are orders of
magnitude higher in Australia than southern Europe (Fran-
ceschi et al., 1996). Unlike our investigation, others have not
examined anatomic subsites individually but rather have
grouped sites based on their opportunity for sun-exposure.
A study by Buettner and Raasch (1998) that included only
single lesions per person reported BCC incidence was highest
on the combined subsites of lip, orbit, nasolabial, ear, nose,
and cheek. This agrees with our estimates but we have gone
further showing the occurrence of BCC on the nose and
cheek/perioral region to be the greatest. In addition, we have
shown that anatomic subsite distribution of BCC is similar
whether people are singly or multiply affected. The top five
subsites (nose, cheek, eye area, forehead, and ears) corre-
spond closely to the subsites that receive the greatest UV
exposure (Diffey et al., 1979), apart from the forehead which
receives the second highest level of UV exposure (Diffey
et al., 1979) but had the fourth highest incidence of BCCs.
This difference could be explained by the sun protection of
the forehead offered by hair cover (which can decrease solar
UV exposure by up to 80% (Green et al., 2006)), or by caps or
hats. Diffey et al. (1979) did not measure the mean UV
exposure of the ears, however, it is likely the ears receive sun
protection in a similar way to that of the forehead.
The anatomic site distribution of BCCs on nonfacial regions
was less predictable and not as directly associated with general
UV exposure. For example, the more highly sun-exposed hand
Table 2. Age-specific incidence rates of basal cell carcinoma in Queensland, Australia, 1997–20061
All persons with BCC Persons with single BCC Persons with multiple BCC
Number of
persons
Person
years
Incidence rate
(95% CI)
Number of
persons
Person
years
Incidence rate
(95% CI)
Number of
persons
Person
years
Incidence rate
(95% CI)
Male
Age2 (years)
20–39 5 497 1,005 (210–1,982) 3 476 630 (0–1,425) 2 497 402 (0–1,062)
40–59 46 2,575 1,786 (1,319–2,269) 20 2,354 849 (509–1,218) 26 2,575 1,010 (649–1,393)
60+ 100 2,531 3,950 (3,349–4,555) 53 2,027 2,614 (2,014–3,236) 47 2,531 1,856 (1,399–2,335)
Weighted
average3
151 5,604 1,813 (1,392–2,303) 76 4,858 1,068 (729–1,475) 75 5,604 877 (607–1,222)
Female
Age2 (years)
20–39 2 538 372 (0–947) 1 530 189 (0–614) 1 538 186 (0–623)
40–59 61 3,515 1,736 (1,350–2,141) 40 3,316 1,206 (863–1,569) 21 3,515 597 (357–860)
60+ 87 3,209 2,711 (2,228–3,188) 45 2,778 1,620 (1,184–2,060) 42 3,209 1,309 (951–1,678)
Weighted
average3
150 7,261 1,269 (1,008–1,582) 86 6,624 801 (602–1,047) 64 7,261 533 (363–763)
Total3 301 12,866 1,541 (1,286–1,829) 162 11,482 935 (737–1,165) 139 12,866 705 (539–905)
BCC, basal cell carcinoma. CI, confidence interval.
1Incidence per 100,000 person years at risk.
2Age at the date of diagnosis.
3Age standardized to the standard world population (Ahmad et al., 2001).
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had a much lower proportion of BCCs compared to the forearm
and upper arm, in agreement with previous reports (Pearl and
Scott, 1986; Buettner and Raasch, 1998).
The strengths of this study were the longitudinal data
collection and the community-based sample, with complete
ascertainment of all confirmed BCCs in a 10-year period.
Although complete records of participants’ skin cancers were
available from 1992, we purposely began observation for this
incidence study in 1997 to avoid the unusually close
dermatological surveillance participants received during the
prevention trial (Valery et al., 2004). Since the completion of
the trial, we have investigated the long-term protective effect
of sunscreen use against BCC and found no significant
change in BCC incidence (Van der Pols et al., 2006b). We
furthermore showed that there was no impact of the
sunscreen intervention on BCC tumor incidence measures
in this follow-up study.
Present study participants were representative of the
original community-based population with respect to sex,
skin color, and frequency of outdoor occupations. However,
there were a slightly higher proportion of people aged 40–59
years included in the current study which may explain why
the participants were also somewhat more likely to have had
a BCC before baseline compared to those who were not
included (18 versus 13%, respectively). It is therefore possible
that our incidence estimates are slightly inflated compared to
those in the community at large, though this bias could not
explain more than a small proportion of the very high
magnitude of multiple BCC occurrences observed.
This report provides insight into the potential magnitude of
the BCC tumor burden in Caucasian populations, especially
those living or frequently holidaying in places of intense sun
exposure. It is apparent that the actual BCC tumor burden is
greater in a population than is apparent simply from
incidence rates of BCC. There is not only the opportunity
for early detection of BCC among people previously
affected, but also the evidence about anatomic sites of BCC
predilection can be translated directly into specific evidence-
based health messages about sun protection. The prevention
of BCC can be achieved by the avoidance of excessive UV
exposure especially to the head and neck, and in particular,
the nose.
MATERIALS AND METHODS
The Nambour Skin Cancer Study
Study participants were originally randomly selected in 1986 from
the electoral register of all adult residents of the subtropical
Queensland township of Nambour (latitude 261S) for a baseline
study of skin cancer (Green et al., 1988). A total of 2,095 participants
(70%) provided written informed consent to take part. They were
representative of the community with regard to phenotypic and sun
exposure skin cancer risk factors (Green et al., 1988). Of these,
1,621 (77%) participated in a field trial to assess sunscreen
application and b-carotene supplementation in skin cancer preven-
tion (1992–1996). Detailed descriptions of the community sample,
field trial, and its long-term outcomes are published (Green et al.,
1999; Van der Pols et al., 2006a, b). Upon conclusion of the trial in
1996, participants were invited to take part in a follow-up study of
skin cancer. Continuing participants consented to have subsequently
diagnosed skin cancers notified to the investigators by regional
Queensland Pathology Laboratories, allowing 100% ascertainment
of all histologically confirmed BCCs. No participants were
immunosuppressed or affected by Gorlin’s syndrome. Long-term
skin cancer follow-up continued to 31 December 2006. The
Queensland Institute of Medical Research Ethics Committee
provided ethical approval.
Table 3. Site-specific and surface-area-standardized
incidence rates for all persons affected by basal cell
carcinoma in Queensland, Australia, 1997–20061,2,3
Anatomical site
Number of
tumors (%)
Incidence
rate
per 1,000
Surface-area-
standardized
incidence rate
per 1,000
Head and neck
Overall 379 (57) 17.3 223.6
Scalp 5 0.2 6.3
Forehead/temple 61 3.0 426.6
Ears 38 1.8 366.5
Eyes 31 1.6 1,609.6
Nose 110 5.2 2,584.3
Cheek/perioral 64 2.8 2,122.6
Chin/jaw 14 0.6 121.2
Neck 47 1.7 72.7
Trunk
Overall 111 (17) 4.7 20.8
Back 83 3.6 37.8
Chest/abdomen 27 1.1 19.2
Limbs
Overall 172 (26) 7.9 13.9
Arms
Overall 118 (18) 5.0 30.4
Upper arm4 63 2.8 35.6
Lower arm 36 1.4 23.2
Hands 9 0.3 13.4
Legs
Overall 54 (8) 2.8 7.1
Hip and upper leg 4 0.2 0.9
Lower leg 45 2.5 17.7
Feet 2 0.06 0.9
Italic values provide overall estimates for anatomic regions.
1Surface-area-standardized and age-standardized per 1,000 body units
per year.
2Anatomical site was unknown for one BCC and BCCs with unspecified
subsites were excluded.
3Surface-area-standardized incidence rates may reach beyond 1,000 per
1,000 body units per year because people who have been affected by BCC
more than once are included in the calculations.
4Calculations for the upper arm include the shoulder.
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Data collection
All BCCs were verified histologically. Investigators abstracted details
of anatomic site from pathology reports. Because the same tumor
may be histologically diagnosed twice, at initial biopsy/excision and
again if reexcised, all records of apparently multiple BCCs diagnosed
within a 6-month period in the same person and on the same
anatomic site were crosschecked to identify duplicate reports.
Recurrent BCCs diagnosed at the sites of earlier primary lesions
were excluded. Information on skin cancer history before 1997 was
based on skin cancers identified during skin examinations and
surveys conducted among the participants between 1986 and 1996
(Green et al., 1988, 1994, 1996; Green and Battistutta, 1990), and
on self-reports of any type of skin cancer before 1986 (Green et al.,
1988) with histological verification of the subset of cancers reported
in 1985–1986 (Green and Battistutta, 1990).
Data analysis
All new BCCs that occurred among participants during 1997–2006
were included. Person- and tumor-based incidence rates of
confirmed BCCs were calculated over the 10-year period 1 January
1997 to 31 December 2006, and were directly age-standardized to
the standard world population (Ahmad et al., 2001). For person-
based incidence rate calculation, the number of people with a
histological BCC diagnosis was divided by the total number of pyar
for the observation period and expressed per 100,000 pyar. Person
years were counted until either date of death, date of withdrawal
from the study, or the end date of observation, whichever came first.
Calculations were carried out separately for persons with single and
multiple BCCs treated during the 10-year study period. For
calculation of site-specific incidence rates, the numbers of histolo-
gically confirmed tumors on each site were divided by the total
number of pyar and rates were standardized for relative surface area
(Pearl and Scott, 1986; Buettner and Raasch, 1998) and expressed
per 1,000 body units, where each body unit is equivalent to the total
surface area of the skin of a person. For example, the calculation of
rates for the nose, age-standardized incidence rates were divided by
0.002 because the nose is an estimated 0.02% of the total body unit/
surface area. These rates permit a direct comparison of the BCC
incidence per unit area of skin on different anatomic sites. Median
time interval between BCCs was estimated using PROC LIFETEST.
Confidence intervals were calculated using bias-corrected boot-
strap methods (Efron and Tibshirani, 1993). We resampled from the
original skewed distribution of cases 10,000 times with replacement.
Statistical analyses were conducted using Stata version 9.1
(StataCorp, College Station, TX) and SAS version 9.1 (SAS Institute
Inc., Cary, NC). Po0.05 was considered statistically significant.
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